Fig. 2: Primary outcome. | Nature Communications

Fig. 2: Primary outcome.

From: A randomized non-inferiority trial of therapeutic strategy with immunosuppressants versus biologics for Vogt-Koyanagi-Harada disease

Fig. 2

The primary outcome was the change from baseline in best-corrected visual acuity measured as Early Treatment Diabetic Retinopathy Study (ETDRS) score at week 26. The least-squares mean changes from baseline and between-group differences were adjusted for baseline value, disease phase, and the correlation between the eyes of the same patient, with the use of the generalized estimating equation. n = 220 independent eyes for overall patients; n = 54 independent eyes for early-phase patients; n = 166 independent eyes for late-phase patients. Source data are provided as a Source Data file.

Back to article page